OptiNose, Inc. (OPTN): Price and Financial Metrics


OptiNose, Inc. (OPTN): $2.13

-0.07 (-3.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OPTN POWR Grades


  • Growth is the dimension where OPTN ranks best; there it ranks ahead of 87.32% of US stocks.
  • The strongest trend for OPTN is in Value, which has been heading up over the past 161 days.
  • OPTN's current lowest rank is in the Momentum metric (where it is better than 9.44% of US stocks).

OPTN Stock Summary

  • OptiNose Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 3.69% of US listed stocks.
  • OPTN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 2.24% of US stocks.
  • Revenue growth over the past 12 months for OptiNose Inc comes in at 56.19%, a number that bests 87.09% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to OptiNose Inc, a group of peers worth examining would be TELA, HTGM, FCEL, BIOL, and PWFL.
  • OPTN's SEC filings can be seen here. And to visit OptiNose Inc's official web site, go to www.optinose.com.

OPTN Valuation Summary

  • In comparison to the median Healthcare stock, OPTN's price/sales ratio is 77.97% lower, now standing at 2.5.
  • Over the past 47 months, OPTN's price/earnings ratio has gone down 72.4.
  • Over the past 47 months, OPTN's price/sales ratio has gone down 11.7.

Below are key valuation metrics over time for OPTN.

Stock Date P/S P/B P/E EV/EBIT
OPTN 2021-08-31 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-30 2.5 -4.3 -1.7 -2.4
OPTN 2021-08-27 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-26 2.5 -4.1 -1.6 -2.3
OPTN 2021-08-25 2.4 -4.0 -1.6 -2.3
OPTN 2021-08-24 2.4 -4.0 -1.6 -2.3

OPTN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPTN has a Quality Grade of C, ranking ahead of 30.77% of graded US stocks.
  • OPTN's asset turnover comes in at 0.372 -- ranking 127th of 682 Pharmaceutical Products stocks.
  • ALT, FOLD, and RDUS are the stocks whose asset turnover ratios are most correlated with OPTN.

The table below shows OPTN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.372 0.861 -0.687
2021-03-31 0.317 0.854 -0.758
2020-12-31 0.282 0.847 -0.844
2020-09-30 0.258 0.832 -0.995
2020-06-30 0.251 0.840 -1.196
2020-03-31 0.225 0.841 -1.335

OPTN Price Target

For more insight on analysts targets of OPTN, see our OPTN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.4 (Strong Buy)

OPTN Stock Price Chart Interactive Chart >

Price chart for OPTN

OPTN Price/Volume Stats

Current price $2.13 52-week high $4.85
Prev. close $2.20 52-week low $1.46
Day low $2.11 Volume 129,304
Day high $2.23 Avg. volume 312,054
50-day MA $1.79 Dividend yield N/A
200-day MA $2.73 Market Cap 175.09M

OptiNose, Inc. (OPTN) Company Bio


OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.


OPTN Latest News Stream


Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream


Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Yahoo | December 17, 2021

Optinose Announces Appointment of Two New Members to Board of Directors

YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors. Eric and Kyle currently serve as Partners at MVM Partners LLP (MVM), a growth equity firm that has invested in innovative, high growth healthcare businesses since 1997. With teams in Boston and London, MVM has a succ

Yahoo | December 13, 2021

OptiNose (NASDAQ:OPTN) Downgraded by Zacks Investment Research

OptiNose (NASDAQ:OPTN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or [] The post OptiNose (NASDAQ:OPTN) Downgraded by Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 9, 2021

State Street Corp Sells 483,816 Shares of OptiNose, Inc. (NASDAQ:OPTN)

State Street Corp lessened its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN) by 83.7% during the second quarter, Holdings Channel.com reports. The firm owned 93,995 shares of the companys stock after selling 483,816 shares during the quarter. State Street Corps holdings in OptiNose were worth $292,000 at the end of the most recent quarter. Several []

Dakota Financial News | December 9, 2021

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo 30.67%
3-mo -24.73%
6-mo -23.93%
1-year -47.92%
3-year -67.58%
5-year N/A
YTD 31.48%
2021 -60.87%
2020 -55.10%
2019 48.71%
2018 -67.20%
2017 N/A

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8372 seconds.